Diamyd Net Income Applicable To Common Shares from 2010 to 2026

DMN Stock  EUR 1.50  0.01  0.67%   
Diamyd Medical's Net Loss is decreasing over the last several years with slightly volatile swings. Net Loss is estimated to finish at about -85.7 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-90.2 M
Current Value
-85.7 M
Quarterly Volatility
44.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Diamyd Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Diamyd Medical's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 2.2 M or Interest Expense of 0.0, as well as many indicators such as . Diamyd financial statements analysis is a perfect complement when working with Diamyd Medical Valuation or Volatility modules.
  
This module can also supplement various Diamyd Medical Technical models . Check out the analysis of Diamyd Medical Correlation against competitors.
The Net Income Applicable To Common Shares trend for Diamyd Medical AB offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Diamyd Medical is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Diamyd Medical's Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Diamyd Medical AB over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Diamyd Medical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Diamyd Medical's overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Diamyd Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(47,553,944)
Coefficient Of Variation(93.52)
Mean Deviation34,668,515
Median(32,008,000)
Standard Deviation44,471,746
Sample Variance1977.7T
Range163.6M
R-Value(0.51)
Mean Square Error1550.8T
R-Squared0.26
Significance0.03
Slope(4,532,540)
Total Sum of Squares31643.8T

Diamyd Net Income Applicable To Common Shares History

2026-85.7 M
2025-90.2 M
2022-100.2 M
2021-103.5 M
202060 M
20199.7 M
2018-36.6 M

About Diamyd Medical Financial Statements

Diamyd Medical stakeholders use historical fundamental indicators, such as Diamyd Medical's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Diamyd Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Diamyd Medical's assets and liabilities are reflected in the revenues and expenses on Diamyd Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Diamyd Medical AB. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-90.2 M-85.7 M

Currently Active Assets on Macroaxis

Other Information on Investing in Diamyd Stock

Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.